Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.

The Cochrane database of systematic reviews - 8 Sept 2017

Schuit Ewoud, Panagiotou Orestis A, Munafò Marcus R, Bennett Derrick A, Bergen Andrew W, David Sean P

Abstract excerpt

BACKGROUND: Smoking cessation therapies are not effective for all smokers, and researchers are interested in identifying those subgroups of individuals (e.g. based on genotype) who respond best to specific treatments. OBJECTIVES: To assess whether quit rates vary by genetically informed biomarkers within pharmacotherapy treatment arms and as compared with placebo. To assess the effects of pharmacotherapies for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CHRNA3 gene
Share to Genetic Markers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Polymorphism, Single Nucleotide

Share to Randomized Controlled Trials as Topic

Share to Smoking

Share to Smoking Cessation

Share to Time Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 28884473
DOI: 10.1002/14651858.CD011823.pub2
PMCID: PMC6483659

Genes

CHRNA3
CHRNA5
DRD4
EGLN2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.PMID 28884473Read ↗

Smoking cessation treatment: pharmacogenetic assessment.Semantic proximity Read ↗

The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Pharmacogenetic Optimization of Smoking Cessation Treatment.Semantic proximity Read ↗

Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolismSemantic proximity Read ↗

Studies towards stratified approaches to smoking cessation with a focus on South Asians and effectiveness of vareniclineSemantic proximity Read ↗

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Semantic proximity Read ↗

Pharmacogenetics of smoking cessation therapySemantic proximity Read ↗

The Role of Pharmacogenetics in Smoking.Semantic proximity Read ↗

Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans.Semantic proximity Read ↗

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.Semantic proximity Read ↗

Helping smokers quit through pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.